Lifeline extended for lymphoma patients on experimental drug
NCT ID NCT05688475
Summary
This study allows a small group of lymphoma patients who have been successfully taking the experimental drug CC-122 for over five years in earlier trials to continue receiving it. The main goal is to monitor the long-term safety of the treatment for these specific patients. It is not testing the drug for new patients, but providing continued access to those already benefiting from it.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Local Institution - 100
New York, New York, 10065, United States
-
Local Institution - 101
Nashville, Tennessee, 37203, United States
-
Local Institution - 102
Madison, Wisconsin, 53792, United States
-
Local Institution - 300
Bordeaux, 33076, France
-
Local Institution - 301
Marseille, 13273, France
-
Local Institution - 400
Amsterdam, 1105, Netherlands
-
Local Institution - 500
Koto-ku, Tokyo, 1358550, Japan
Conditions
Explore the condition pages connected to this study.